These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8106151)

  • 1. Dynorphin agonist therapy of Parkinson's disease.
    Giuffra M; Mouradian MM; Davis TL; Ownby J; Chase TN
    Clin Neuropharmacol; 1993 Oct; 16(5):444-7. PubMed ID: 8106151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease.
    Rascol O; Lees AJ; Senard JM; Pirtosek Z; Montastruc JL; Fuell D
    Clin Neuropharmacol; 1996 Jun; 19(3):234-45. PubMed ID: 8726542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dihydroergocryptine in the treatment of Parkinson's disease: a six months' double-blind clinical trial.
    Martignoni E; Pacchetti C; Sibilla L; Bruggi P; Pedevilla M; Nappi G
    Clin Neuropharmacol; 1991 Feb; 14(1):78-83. PubMed ID: 1903079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
    Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
    Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.
    Lieberman A; Imke S; Muenter M; Wheeler K; Ahlskog JE; Matsumoto JY; Maraganore DM; Wright KF; Schoenfelder J
    Neurology; 1993 Oct; 43(10):1981-4. PubMed ID: 8105422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.
    Juncos JL; Fabbrini G; Mouradian MM; Serrati C; Kask AM; Chase TN
    J Neurol Neurosurg Psychiatry; 1987 Feb; 50(2):194-8. PubMed ID: 3572434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease.
    Bara-Jimenez W; Sherzai A; Dimitrova T; Favit A; Bibbiani F; Gillespie M; Morris MJ; Mouradian MM; Chase TN
    Neurology; 2003 Aug; 61(3):293-6. PubMed ID: 12913186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
    Giménez-Roldán S; Tolosa E; Burguera JA; Chacón J; Liaño H; Forcadell F
    Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased ratio of carbidopa to levodopa in treatment of Parkinson's disease.
    Tourtellotte WW; Syndulko K; Potvin AR; Hirsch SB; Potvin JH
    Arch Neurol; 1980 Nov; 37(11):723-6. PubMed ID: 7436817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Parkinson's disease with pergolide: a double-blind study.
    Ahlskog JE; Muenter MD
    Mayo Clin Proc; 1988 Oct; 63(10):969-78. PubMed ID: 3050300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.
    Merello M; Lees AJ; Webster R; Bovingdon M; Gordin A
    J Neurol Neurosurg Psychiatry; 1994 Feb; 57(2):186-9. PubMed ID: 8126502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.
    Hauser RA; Hsu A; Kell S; Espay AJ; Sethi K; Stacy M; Ondo W; O'Connell M; Gupta S;
    Lancet Neurol; 2013 Apr; 12(4):346-56. PubMed ID: 23485610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased dosage of carbidopa in patients with Parkinson's disease receiving low doses of levodopa. A pilot study.
    Hoehn MM
    Arch Neurol; 1980 Mar; 37(3):146-9. PubMed ID: 7356419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
    Olanow CW; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes JD; Jankovic J
    Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I.
    Kurth MC; Adler CH; Hilaire MS; Singer C; Waters C; LeWitt P; Chernik DA; Dorflinger EE; Yoo K
    Neurology; 1997 Jan; 48(1):81-7. PubMed ID: 9008498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.